Abstract
Objective To analyze the clinical effect of tirofiban hydrochloride on no/slow reflow in patients with acute myocardial infarction who underwent percutaneous coronary intervention(PCI). Methods From May 2013 to May 2015, 54 patients with acute myocardial infarction treated with PCI with no/slow-reflow were randomly divided into two groups, with 27 cases in each group. Control group received conventional treatment, and observation group received tirofiban hydrochloride treatment. The effects between the two groups were compared. Results The blood flow after PCI in observation group was significantly better than that in the control group, the difference was significant (P<0.05). The peak and average value of cTnI and CK-MB in observation group were significantly lower than those in the control group, the differences were significant (P<0.05), and there was no postoperative cardiac event or bleeding. Conclusions Tirofiban hydrochloride in treatment of acute myocardial infarction after direct PCI no/slow-reflow can significantly reduce the peak and average value of cTnI and CK-MB, it is worthy of promotion. Key words: Tirofiban hydrochloride; Acute myocardial infarction; Percutaneous transluminal coronary intervention; no/slow-reflow
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call